C07K 16/3015
Breast
Official title: {Breast}
C07K16/3015 (Breast) appears on 674 US grants and 1,078 published applications in this corpus.
Search patents in C07K- Granted patents
- 674
- Published applications
- 1,078
- Assignees
- 391
- Inventors
- 1,617
- Latest grant
- 18 Aug 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1984 | 2 | 0 |
| 1985 | 1 | 0 |
| 1986 | 3 | 0 |
| 1987 | 2 | 0 |
| 1988 | 4 | 0 |
| 1989 | 2 | 0 |
| 1990 | 5 | 0 |
| 1991 | 6 | 0 |
| 1992 | 3 | 0 |
| 1993 | 2 | 0 |
| 1994 | 2 | 0 |
| 1995 | 1 | 0 |
| 1996 | 6 | 0 |
| 1997 | 11 | 0 |
| 1998 | 18 | 0 |
| 1999 | 17 | 0 |
| 2000 | 7 | 0 |
| 2001 | 9 | 0 |
| 2002 | 4 | 10 |
| 2003 | 6 | 28 |
| 2004 | 7 | 30 |
| 2005 | 7 | 32 |
| 2006 | 11 | 29 |
| 2007 | 9 | 29 |
| 2008 | 15 | 45 |
| 2009 | 13 | 35 |
| 2010 | 10 | 18 |
| 2011 | 14 | 33 |
| 2012 | 11 | 25 |
| 2013 | 17 | 33 |
| 2014 | 24 | 55 |
| 2015 | 29 | 64 |
| 2016 | 56 | 112 |
| 2017 | 49 | 136 |
| 2018 | 55 | 67 |
| 2019 | 63 | 67 |
| 2020 | 47 | 57 |
| 2021 | 30 | 38 |
| 2022 | 33 | 37 |
| 2023 | 25 | 33 |
| 2024 | 16 | 31 |
| 2025 | 15 | 20 |
| 2026 | 7 | 14 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Targeting gene amplification in cancer using triplex formation as a therapeutic strategy18 Aug 2026US 12,709,645 B2Yale University
- Polypeptide formulations comprising crystal or amorphous polypeptides and vitamin E26 May 2026US 12,636,257 B2Bhami's Research Laboratory, Pvt. Ltd.
- Assays for TIMP2 having improved performance in biological samples12 May 2026US 12,624,121 B2Biomerieux
- Affinity maturated TAG72 specific single chain antibodies12 May 2026US 12,624,122 B2H. Lee Moffitt Cancer Center and Research Institute, Inc.
- Modified Fc-regions to enhance functional affinity of antibodies and antigen binding fragments thereof7 Apr 2026US 12,595,313 B2Scancell Limited
- Anti-HER2 Antibodies and Immunoconjugates1 Oct 2026US 2026/0297214 A1Genentech, Inc.
- Targeting gene amplification in cancer using triplex formation as a therapeutic strategy10 Sep 2026US 2026/0265407 A1Yale University
- Anti-vista antibodies and fragments13 Aug 2026US 2026/0234264 A1Janssen Pharmaceutica NV
- Cancer immunotherapies to promote hyperacute rejection2 Jul 2026US 2026/0183409 A1Cornell University
- Pharmaceutical composition for treatment and prevention of cancers25 Jun 2026US 2026/0176372 A1Toray Industries, Inc.
Most cited
By later US patents
- Optimized Fc variants463US 7,317,091 B2Xencor, Inc. · 2008
- Monoclonal antibodies directed to the HER2 receptor435US 5,677,171 AGenentech, Inc. · 1997
- Metal chelate conjugated monoclonal antibodies310US 4,472,509 A1984
- Monoclonal antibodies directed to the her2 receptor254US 5,770,195 AGenentech, Inc. · 1998
- Compositions for targeting the vasculature of solid tumors254US 6,051,230 ABoard of Regents, The University of Texas System · 2000